Contact us with no obligation
1 (877) 583-5348
24 Hours/ 7 days a week

FDA: Bydureon May Cause Pancreatic Cancer


152498590In March 2013, the Food and Drug Administration announced new evidence indicating Bydureon and other diabetic drugs can cause “pre-cancerous cellular changes” in the pancreas. Researchers found Bydureon can increase pancreatic mass by more than 40%, potentially leading to cancer.

Pancreatic cancer is one of the most deadly and least treatable forms of cancer. It will kill nearly 38,500 Americans in 2013, according to the American Cancer Society.

Treating any form of cancer is emotionally, physically and financially draining. You shouldn’t have to bear these expenses.

If you suspect Bydureon caused cancer in yourself or a loved one, you need to get legal help. Contact us today to learn about your legal rights and how Ferrer, Poirot & Wansbrough may be able to help you seek compensation from the maker of this dangerous drug for your suffering and your expenses.

Warnings Raised Several Times

Research published in Gastroenterology has linked exenatide, an injectable diabetes drug sold under the names Bydureon and Byetta, to serious dangers, including:

By the time the FDA approved Bydureon in January 2012, the potential dangers of exenatide were well-known.

  • The FDA warned exenatide was linked to an increased risk of pancreatitis, a risk factor for pancreatic cancer, as early as 2007.
  • In 2009, the FDA ordered further studies of Byetta and said patients need to be aware of “serious risks” associated with it.

Researchers published these findings after studying hundreds of complaints filed with the Food and Drug Administration between 2004 and 2009.

Get Help Now

Contact us today by filling out the form on this page for a free, no-obligation consultation. We may be able to seek compensation for your medical expenses and for you and your family’s suffering.

Contact us today. Time is limited to seek justice, so don’t delay. Call Ferrer, Poirot & Wansbrough toll-free at 1 (877) 583-5348.